BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1711 related articles for article (PubMed ID: 25987504)

  • 1. The application of genome editing in studying hearing loss.
    Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
    Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of CRISPR/Cas9 genome editing to the study and treatment of disease.
    Pellagatti A; Dolatshad H; Valletta S; Boultwood J
    Arch Toxicol; 2015 Jul; 89(7):1023-34. PubMed ID: 25827103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma.
    Liu T; Shen JK; Li Z; Choy E; Hornicek FJ; Duan Z
    Cancer Lett; 2016 Apr; 373(1):109-118. PubMed ID: 26806808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss.
    Farooq R; Hussain K; Tariq M; Farooq A; Mustafa M
    J Appl Genet; 2020 Feb; 61(1):51-65. PubMed ID: 31912450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Progress in CRISPR/Cas9 Technology.
    Mei Y; Wang Y; Chen H; Sun ZS; Ju XD
    J Genet Genomics; 2016 Feb; 43(2):63-75. PubMed ID: 26924689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-mediated correction of human genetic disease.
    Men K; Duan X; He Z; Yang Y; Yao S; Wei Y
    Sci China Life Sci; 2017 May; 60(5):447-457. PubMed ID: 28534256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in genome editing for genetic hearing loss.
    Ding N; Lee S; Lieber-Kotz M; Yang J; Gao X
    Adv Drug Deliv Rev; 2021 Jan; 168():118-133. PubMed ID: 32387678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exogenous gene integration mediated by genome editing technologies in zebrafish.
    Morita H; Taimatsu K; Yanagi K; Kawahara A
    Bioengineered; 2017 May; 8(3):287-295. PubMed ID: 28272984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The application of CRISPR-Cas9 gene editing technology in viral infection diseases].
    Yin LJ; Hu SQ; Guo F
    Yi Chuan; 2015 May; 37(5):412-8. PubMed ID: 25998428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
    Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
    J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9-mediated genome editing of splicing mutation causing congenital hearing loss.
    Ryu N; Kim MA; Choi DG; Kim YR; Sonn JK; Lee KY; Kim UK
    Gene; 2019 Jun; 703():83-90. PubMed ID: 30898719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome modification by CRISPR/Cas9.
    Ma Y; Zhang L; Huang X
    FEBS J; 2014 Dec; 281(23):5186-93. PubMed ID: 25315507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy.
    Gori JL; Hsu PD; Maeder ML; Shen S; Welstead GG; Bumcrot D
    Hum Gene Ther; 2015 Jul; 26(7):443-51. PubMed ID: 26068008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Generation of Zebrafish Mariner Model Using the CRISPR/Cas9 System.
    Zou B; Desmidt AA; Mittal R; Yan D; Richmond M; Tekin M; Liu XZ; Lu Z
    Anat Rec (Hoboken); 2020 Mar; 303(3):556-562. PubMed ID: 31260171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation.
    Wang H; Sun W
    Cancer Lett; 2017 Jan; 385():137-143. PubMed ID: 27815036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods.
    Jo YI; Suresh B; Kim H; Ramakrishna S
    Biochim Biophys Acta; 2015 Dec; 1856(2):234-43. PubMed ID: 26434948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Smart Programmable CRISPR Technology: A Next Generation Genome Editing Tool for Investigators.
    Chakraborty C; Teoh SL; Das S
    Curr Drug Targets; 2017; 18(14):1653-1663. PubMed ID: 27231109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in therapeutic CRISPR/Cas9 genome editing.
    Savić N; Schwank G
    Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of microsatellite instability in CRISPR/Cas9 editing mice.
    Huo X; Du Y; Lu J; Guo M; Li Z; Zhang S; Li X; Chen Z; Du X
    Mutat Res; 2017 Mar; 797-799():1-6. PubMed ID: 28284774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 86.